statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response

As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response PR Newswire...

Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options

Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options...

Arvinas, Inc. (NASDAQ:ARVN) Short Interest Down 5.1% in March

Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) was the recipient of a significant decrease in short interest during the month of March. As of March 15th, there was short interest totalling 7,920,000...

Arvinas (NASDAQ:ARVN) Shares Gap Down to $42.60

Arvinas, Inc. (NASDAQ:ARVN  Get Free Report)s stock price gapped down before the market opened on Tuesday . The stock had previously closed at $42.60, but opened at $41.23. Arvinas...

Arvinas names Noah Berkowitz as Chief Medical Officer

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

- Awards Dr. Berkowitz an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) -NEW HAVEN, Conn., March 18, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage...

Arvinas (ARVN, $44.74) entered Downtrend as Momentum indicator drops below 0 level on Mar 14, 2024

This indicator may be signaling that ARVN's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Arvinas (ARVN, $46.48) entered Uptrend as Momentum indicator ascends above 0 level on Mar 13, 2024

This indicator may be signaling ARVN's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...

Arvinas (ARVN, $45.51) entered Downtrend as Momentum indicator drops below 0 level on Mar 11, 2024

Schonfeld Strategic Advisors LLC Has $1.26 Million Stake in Arvinas, Inc. (NASDAQ:ARVN)

Schonfeld Strategic Advisors LLC reduced its position in shares of Arvinas, Inc. (NASDAQ:ARVN  Free Report) by 2.7% in the 3rd quarter, according to its most recent Form 13F filing with the...

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.

Volume	393,067.00
52-Wk High	$53.08
52-Wk Low	$13.57

ARVN Arvinas Inc

About

Feed

News

Sentiment

Earnings

Fundamentals